GSK’s vaccines group — including R&D — faces heavy job cuts in latest restructuring
Emma WalmsleyGSK’s top executives stayed mum yesterday on the location and number of layoffs likely to occur as the pharma giant integrated their vaccine R&D ops with the pharma side of the business. But it’s clear now that the ax will fall hard on the European vaccine group, with 935 jobs on the chopping block in Belgium and many more rumored cuts under discussion.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
